Monogenic autoimmune diseases of the endocrine system

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 10, 2016, Pages 862-872

  Johnson, Matthew B ^a   Hattersley, Andrew T ^a   Flanagan, Sarah E ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIFUNGAL AGENT; AUTOIMMUNE REGULATOR PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6 RECEPTOR; RAPAMYCIN; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UBIQUITIN PROTEIN LIGASE E3;

AIRE GENE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNE THYROIDITIS; CLINICAL FEATURE; COMMON VARIABLE IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY 8 WITH AUTOIMMUNITY; DISEASE SEVERITY; FOXP3 GENE; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IL2RA GENE; IMMUNODEFICIENCY 31C SYNDROME; IMMUNODEFICIENCY 41 WITH LYMPHOPROLIFERATION AND AUTOIMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFANTILE ONSET MULTISYSTEM AUTOIMMUNE DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; ITCH GENE; LRBA GENE; MONOGENIC AUTOIMMUNE POLYENDOCRINOPATHY; MONOGENIC DISORDER; MULTISYSTEM AUTOIMMUNE DISEASE FACIAL DYSMORPHISM; NONHUMAN; ONSET AGE; PARENTERAL NUTRITION; PATHOGENESIS; PATIENT EDUCATION; PHENOTYPE; POLYENDOCRINOPATHY; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; STAT1 GENE; STAT3 GENE; ENDOCRINE DISEASE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MUTATION; PATHOPHYSIOLOGY;

AGE OF ONSET; AUTOIMMUNE DISEASES; ENDOCRINE SYSTEM DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; PHENOTYPE;

EID: 84990062012     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30095-X     Document Type: Review

References (79)

1. 1 Garmendia Madariaga, A, Santos Palacios, S, Guillen-Grima, F, Galofre, JC, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99 (2014), 923–931.
2. 2 Boelaert, K, Newby, PR, Simmonds, MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 123 (2010), e1–e9.
3. 3 Brix, TH, Kyvik, KO, Christensen, K, Hegedus, L, Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 86 (2001), 930–934.
4. 4 Redondo, MJ, Jeffrey, J, Fain, PR, Eisenbarth, GS, Orban, T, Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 359 (2008), 2849–2850.
5. 5 Thomsen, SF, Duffy, DL, Kyvik, KO, Skytthe, A, Backer, V, Relationship between type 1 diabetes and atopic diseases in a twin population. Allergy 66 (2011), 645–647.
6. 6 Chu, X, Pan, CM, Zhao, SX, et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet 43 (2011), 897–901.
7. 7 Polychronakos, C, Li, Q, Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet 12 (2011), 781–792.
8. 8 Burdett, HP, Hastings, E, Hindorff, LA, et al. The NHGRI-EBI Catalog of published genome-wide association studies. http://www.ebi.ac.uk/gwas (accessed Feb 14, 2016).
9. 9 Hansen, PS, Brix, TH, Iachine, I, Kyvik, KO, Hegedus, L, The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol 154 (2006), 29–38.
10. 10 Lee, HJ, Li, CW, Hammerstad, SS, Stefan, M, Tomer, Y, Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun 64 (2015), 82–90.
11. 11 Morran, MP, Vonberg, A, Khadra, A, Pietropaolo, M, Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med 42 (2015), 42–60.
12. 12 Betterle, C, Lazzarotto, F, Presotto, F, Autoimmune polyglandular syndrome type 2: the tip of an iceberg?. Clin Exp Immunology 137 (2004), 225–233.
13. 13 Lo, B, Zhang, K, Lu, W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349 (2015), 436–440.
14. 14 Milner, JD, Vogel, TP, Forbes, L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 125 (2015), 591–599.
15. 15 Husebye, ES, Perheentupa, J, Rautemaa, R, Kampe, O, Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 265 (2009), 514–529.
16. 16 Perheentupa, J, Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 91 (2006), 2843–2850.
17. 17 Valenzise, M, Fierabracci, A, Cappa, M, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: report of seven additional Sicilian patients and overview of the overall series from Sicily. Horm Res Paediatr 82 (2014), 127–132.
18. 18 d'Hennezel, E, Bin Dhuban, K, Torgerson, T, Piccirillo, CA, The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 49 (2012), 291–302.
19. 19 Bezrodnik, L, Caldirola, MS, Seminario, AG, Moreira, I, Gaillard, MI, Follicular bronchiolitis as phenotype associated with CD25 deficiency. Clin Exp Immunol 175 (2014), 227–234.
20. 20 Goudy, K, Aydin, D, Barzaghi, F, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol 146 (2013), 248–261.
21. 21 Sharfe, N, Dadi, HK, Shahar, M, Roifman, CM, Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc Natl Acad Sci USA 94 (1997), 3168–3171.
22. 22 Roifman, CM, Human IL-2 receptor alpha chain deficiency. Pediatr Res 48 (2000), 6–11.
23. 23 Caudy, AA, Reddy, ST, Chatila, T, Atkinson, JP, Verbsky, JW, CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 119 (2007), 482–487.
24. 24 Lohr, NJ, Molleston, JP, Strauss, KA, et al. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am J Hum Genet 86 (2010), 447–453.
25. 25 Lo, B, Zhang, K, Lu, W, et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349 (2015), 436–440.
26. 26 Seidel, MG, Hirschmugl, T, Gamez-Diaz, L, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol 135 (2014), 1384–1390.
27. 27 Lopez-Herrera, G, Tampella, G, Pan-Hammarstrom, Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 90 (2012), 986–1001.
28. 28 Alangari, A, Alsultan, A, Adly, N, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol 130 (2012), 481–488.
29. 29 Burns, SO, Zenner, HL, Plagnol, V, et al. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. J Allergy Clin Immunol 130 (2012), 1428–1432.
30. 30 Revel-Vilk, S, Fischer, U, Keller, B, et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clin Immunol 159 (2015), 84–92.
31. 31 Serwas, NK, Kansu, A, Santos-Valente, E, et al. Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm Bowel Dis 21 (2015), 40–47.
32. 32 Charbonnier, LM, Janssen, E, Chou, J, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol 135 (2015), 217–227.
33. 33 Liu, L, Okada, S, Kong, XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208 (2011), 1635–1648.
34. 34 Uzel, G, Sampaio, EP, Lawrence, MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131 (2013), 1611–1623.
35. 35 Flanagan, SE, Haapaniemi, E, Russell, MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 46 (2014), 812–814.
36. 36 Haapaniemi, EM, Kaustio, M, Rajala, HL, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 125 (2015), 639–648.
37. 37 Wienke, J, Janssen, W, Scholman, R, et al. A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation. Oncotarget 6 (2015), 20037–20042.
38. 38 Stenson, PD, Mort, M, Ball, EV, et al. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133 (2014), 1–9.
39. 39 Pavlic, A, Waltimo-Siren, J, Clinical and microstructural aberrations of enamel of deciduous and permanent teeth in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Arch Oral Biol 54 (2009), 658–665.
40. 40 Aaltonen, J, Bjorses, P, Perheentupa, J, et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 17 (1997), 399–403.
41. 41 Nagamine, K, Peterson, P, Scott, HS, et al. Positional cloning of the APECED gene. Nat Genet 17 (1997), 393–398.
42. 42 Björses, P, Halonen, M, Palvimo, JJ, et al. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet 66 (2000), 378–392.
43. 43 Meloni, A, Perniola, R, Faa, V, Corvaglia, E, Cao, A, Rosatelli, MC, Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from Southern Italy. J Clin Endocrinol Metab 87 (2002), 841–846.
44. 44 Valenzise, M, Wasniewska, M, Mirabelli, S, De Luca, F, Cervato, S, Betterle, C, Identification of two novel mutations in the first Sicilian APECED patient with no R203X mutation in AIRE gene and review of Italian APECED genotypes. Gene 499 (2012), 343–346.
45. 45 Ilmarinen, T, Eskelin, P, Halonen, M, et al. Functional analysis of SAND mutations in AIRE supports dominant inheritance of the G228W mutation. Hum Mutat 26 (2005), 322–331.
46. 46 Cetani, F, Barbesino, G, Borsari, S, et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 86 (2001), 4747–4752.
47. 47 Oftedal, BE, Hellesen, A, Erichsen, MM, et al. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity 42 (2015), 1185–1196.
48. 48 Anderson, MS, Venanzi, ES, Klein, L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298 (2002), 1395–1401.
49. 49 Aschenbrenner, K, D'Cruz, LM, Vollmann, EH, et al. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 8 (2007), 351–358.
50. 50 Powell, BR, Buist, NRM, Stenzel, P, An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J Pediatr 100 (1982), 731–737.
51. 51 De Franco, E, Flanagan, SE, Houghton, JAL, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 386 (2015), 957–963.
52. 52 Rubio-Cabezas, O, Minton, JA, Caswell, R, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 32 (2009), 111–116.
53. 53 McMurchy, AN, Gillies, J, Allan, SE, et al. Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. J Allergy Clin Immunol 126 (2010), 1242–1251.
54. 54 Wildin, RS, Smyk-Pearson, S, Filipovich, AH, Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 39 (2002), 537–545.
55. 55 Gambineri, E, Perroni, L, Passerini, L, et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 122 (2008), 1105–1112.
56. 56 Xavier-da-Silva, MM, Moreira-Filho, CA, Suzuki, E, Patricio, F, Coutinho, A, Carneiro-Sampaio, M, Fetal-onset IPEX: report of two families and review of literature. Clin Immunol 156 (2015), 131–140.
57. 57 Chatila, TA, Blaeser, F, Ho, N, et al. JM2, encoding a fork head–related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 106 (2000), R75–R81.
58. 58 Baris, S, Schulze, I, Ozen, A, et al. Clinical heterogeneity of immunodysregulation, polyendocrinopathy, enteropathy, X-linked: pulmonary involvement as a non-classical disease manifestation. J Clin Immunol 34 (2014), 601–606.
59. 59 Fontenot, JD, Gavin, MA, Rudensky, AY, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 (2003), 330–336.
60. 60 Sehgal, SN, Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 (1998), 335–340.
61. 61 Yong, PL, Russo, P, Sullivan, KE, Use of sirolimus in IPEX and IPEX-like children. J Clin Immunol 28 (2008), 581–587.
62. 62 Barzaghi, F, Passerini, L, Bacchetta, R, Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol, 3, 2012, 211.
63. 63 Zorn, E, Nelson, EA, Mohseni, M, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006), 1571–1579.
64. 64 Matesic, LE, Copeland, NG, Jenkins, NA, Itchy mice: the identification of a new pathway for the development of autoimmunity. Curr Top Microbiol Immunol 321 (2008), 185–200.
65. 65 Masumoto, K, Kitagawa, M, E3 ubiquitin ligases as molecular targets in human oral cancers. Curr Cancer Drug Targets 16 (2015), 130–135.
66. 66 Wu, C, Orozco, C, Boyer, J, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol, 10, 2009, R130.
67. 67 Darnell, JE Jr, Kerr, IM, Stark, GR, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994), 1415–1421.
68. 68 Ioannou, Y, Isenberg, DA, Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 43 (2000), 1431–1442.
69. 69 Al-Ansari, M, Weilert, F, Dickson, G, Interferon-induced haemolytic anaemia in hepatitis C. N Z Med J 121 (2008), 78–81.
70. 70 Zheng, J, van de Veerdonk, FL, Crossland, KL, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol 45 (2015), 2834–2846.
71. 71 Yang, XO, Panopoulos, AD, Nurieva, R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282 (2007), 9358–9363.
72. 72 Holland, SM, DeLeo, FR, Elloumi, HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357 (2007), 1608–1619.
73. 73 Hodge, DR, Hurt, EM, Farrar, WL, The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41 (2005), 2502–2512.
74. 74 Wake, MS, Watson, CJ, STAT3 the oncogene–still eluding therapy?. FEBS J 282 (2015), 2600–2611.
75. 75 Ellard, S, Lango Allen, H, De Franco, E, et al. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 56 (2013), 1958–1963.
76. 76 Siva, N, UK gears up to decode 100 000 genomes from NHS patients. Lancet 385 (2015), 103–104.
77. 77 Bittles, AH, Black, ML, Consanguinity, human evolution, and complex diseases. Proc Natl Acad Sci USA 107:suppl 1 (2010), 1779–1786.
78. 78 Prakash, V, Moore, M, Yanez-Munoz, RJ, Current progress in therapeutic gene editing for monogenic diseases. Mol Ther 24 (2016), 465–474.
79. 79 Genomics England Ltd., Department of Health. The 100,000 Genomes Project. http://www.genomicsengland.co.uk/the-100000-genomes-project/, 2016 (accessed Feb 1, 2016).